| Document |
Document Title |
|
WO/1992/011279A1 |
A new type of D-homo-(16-en)-11$g(b)-aryl-4-estrenes having general formula (I), as well as their pharmacologically acceptable addition salts with acids are disclosed. In formula (I), X stands for an oxygen atom, the hydroxyimino groupin...
|
|
WO/1992/009618A1 |
Described are 8-ene-19, 11$g(b)-bridged steroids of general formula (I) which have a new structural feature in the form of a double bond between the 8 position and the 9 position. Also described is a method of preparing them. The substit...
|
|
WO/1991/004265A1 |
A process is described for producing progesterone derivatives of general formula (I), in which .... is a single or double bond, X is a hydrogen or fluorine atom or a methyl group and V is a methylene, ethylene, ethylidene or vinylidene g...
|
|
WO/1990/003979A2 |
Disclosed are novel classes of anti-androgens including dihydrophenanthrene derivatives, their method of synthesis and their use in treating disorders associated with excessive androgenic activities.
|
|
WO/1990/003184A1 |
The invention claims an iscom matrix which is not a lipid vesicle comprising at least one lipid and at least one saponim but no intentional antigenic determinants and optionally also adjuvants for use as an immunomodulating agent, medici...
|
|
WO/1988/007051A1 |
New 19, 11beta-bridged steroids having the general formula (I), in which R' signifies a methyl or ethyl residue; R2 signifies a hydrogen or chlorine atom or a C1-C4 alkyl residue; B and G, which are identical or different, signify respec...
|
|
WO/1987/005940A1 |
Process for the production of 17aalpha-hydroxy-D-homo-1,4-pregnadiene-3,20-dion of formula (I) characterized by the fact that 3beta,17aalpha-dihydroxy-D-homo-5-pregnene-20-one of formula (II) is fermented with Bacillus lentus ATCC 13805.
|
|
WO/1985/005361A1 |
Novel compounds having the general formula (I), wherein: R1 is hydrogen or an acyl substitutent of formula -(C=O)-R2, wherein: R2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkylene, haloalkyl, aryl, haloaryl or arylalkylene. T...
|
|
JP2024045458A |
The present invention provides steroidal derivative modulators, methods of making and using the same. The present invention relates to steroidal derivative modulators, their production methods and applications. In particular, the present...
|
|
JP7438956B2 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
JP7436385B2 |
The present invention relates to compound of Formula I or a pharmaceutically acceptable salt thereofwherein R1 iswhere the squiggly line indicates the point of attachment to the rest of the molecule;R2 is F orwhere the squiggly line indi...
|
|
JP2024504637A |
Disclosed herein are compounds of formula (IA) in which the variables are defined herein. Pharmaceutical compositions thereof are also provided. In some embodiments, the compounds and compositions provided herein can be used as antioxida...
|
|
JP2024001012A |
The present invention provides a saponin extract useful as an adjuvant for vaccines. A saponin extract containing at least 93% QS-21 main peak and 0.25~3% 2018 components by UV absorbance at 214nm. [Selection diagram] None
|
|
JP2024500245A |
The present invention relates to biosynthetic routes to intermediates of QS-21 molecules, as well as the routes for producing QS-21 molecules, the enzymes involved, the products produced, and the uses of the products.
|
|
JP2023553904A |
Methods for enzymatic modification of saponins, products produced thereby, uses of such products, and also other related aspects. The saponin may be an extract of Quillaja species, such as an extract of Quillaja saponaria molina. [Select...
|
|
JP2023550653A |
Provided herein are compounds of formula (I) or a pharmaceutically acceptable salt thereof, where Ring D and substituents are as defined herein. Also provided are pharmaceutical compositions comprising a compound of formula (I) or a phar...
|
|
JP2023164877A |
To provide compositions and methods for treating or preventing obesity.The present invention relates to analogs of celastrol illustrated by the following compound ERX1001.SELECTED DRAWING: Figure 3
|
|
JP7364587B2 |
The present disclosure is related to the six isomer structures (OBI-821-1990-V1A, OBI-821-1990-V1B, OBI-821-1990-V2A, OBI-821-1990-V2B, OBI-821-1858-A, and OBI-821-1858-B) of isolated OBI-821 adjuvant and the method for evaluating the qu...
|
|
JP2023542500A |
The present invention relates to a conjugate comprising a saponin covalently bound to a ligand of ASGPR, which is a ligand comprising at least one GalNAc moiety, and comprising a saponin and an oligonucleotide covalently bound to a ligan...
|
|
JP2023541192A |
The present disclosure provides synthetic triterpenoids, methods for preparing such synthetic triterpenoids, and the use of such synthetic triterpenoids to treat and treat diseases or disorders such as cancer, particularly brain tumors, ...
|
|
JP7339992B2 |
Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.
|
|
JP2023123515A |
To provide an ursolic acid salt for use in treating disease, which shows superior properties, including effect on skeletal muscle, compared to the ursolic acid itself and other ursolic acid salts, and compositions containing the ursolic ...
|
|
JP2023119042A |
To provide methods for treating diseases.Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, where in the formula (I-I), R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a...
|
|
JP2023533557A |
The present invention provides pentacyclic triterpenoid C-glycosides, methods of preparation and uses thereof, specifically the present invention provides compounds represented by Formula I below, wherein the definitions of each group ar...
|
|
JP2023532680A |
The present invention provides a saponin-based Quillaia saponaria comprising a triterpene aglycone and a first sugar chain and/or a second sugar chain. Saponaria) a saponin derivative, the aglycone core structure comprising a derivatized...
|
|
JP2023531517A |
Provided herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16, R17, R19, RX, RY, and t are defined herein. Also provided herein are ph...
|
|
JP2023530935A |
A soluble extract prepared from a non-woody plant of the genus Hesperaloe and a method for its preparation are disclosed. The extract preferably contains at least one saponin. In a particular example, the method comprises providing bioma...
|
|
JP7281446B2 |
The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used t...
|
|
JP2023054360A |
To provide a method for treating disease.The present invention provides a compound of formula (I) or a salt thereof [where X, L, V, R1, R2, R3 and R4 are as defined herein]. These compounds are inhibitors of 11-hydroxysteroid dehydrogena...
|
|
JP2023513331A |
The present invention relates to novel triterpene derivatives of formula (I) and pharmaceutically acceptable salts thereof. [Chemical 1] R.1,R2,R3,R4,n and ring structure [Chemical 8] is as defined in formula (I). The present invention r...
|
|
JP2023037453A |
To provide methods for isolating and producing 18α-oleanane-type triterpene diglucuronide with higher purity.The method for producing 18α-oleanane-type triterpene diglucuronide according to one aspect of the present invention comprises...
|
|
JP2023507402A |
In some aspects, the disclosure provides compounds of formulas (I) and (II), wherein the variables are defined herein. Further provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided her...
|
|
JP2023507468A |
Kind Code: A1 A compound capable of delivering low-molecular-weight compounds such as peptides and nucleic acids to cells and having superior cytotoxicity to saponin GE1741 is provided. Kind Code: A1 The present invention relates to nove...
|
|
JP2023504428A |
The field of medicinal chemistry and pharmacotherapeutics, specifically 2-cyano-3,12-dioxolane-1,9(11)-diene-17-phenylacrylamide derivative and its preparation method, furthermore said novel compound in the manufacture of anticancer drugs.
|
|
JP2022161990A |
To provide compositions and methods that can be used to deliver (e.g. guide) therapeutic nucleic acids in living subjects.The present invention discloses conjugates that comprise a targeting moiety, a nucleic acid, and arbitrary linking ...
|
|
JP7145188B2 |
Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the trunca...
|
|
JP2022542075A |
The present invention provides a saponin-based saponin derivative comprising a triterpene aglycone and a first and/or second sugar chain, and: an aglycone core structure containing a derivatized aldehyde group and/or said first sugar cha...
|
|
JP2022541545A |
Disclosed herein are compounds of formula (I) in which the variables are defined herein. A pharmaceutical composition thereof is also provided. In some aspects, the compounds and compositions provided herein can be used as antioxidant in...
|
|
JP2022538300A |
As used herein, compounds of formula (1-I), or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided herein a...
|
|
JP2022538299A |
As used herein, compounds of formula I, II, IIIa, IIIb, V, VIa, VIb, VII, VIII, IX, or XI: or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising a compound of formula I, II, IIIa, IIIb, V, VIa, VIb, VII, ...
|
|
JP2022538301A |
As used herein, in part, compounds of formula I, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula I, and methods of using the compounds, eg, in the treatment of CNS-related disord...
|
|
JP7074674B2 |
Disclosed herein are C4 modified oleanolic acid derivatives of the formula:as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions of these derivatives or analog...
|
|
JP2022525768A |
Several MS and natural saponin vaccine adjuvant candidates have been prepared. MS derivatives were prepared by incorporating terminal-functionalized side chains into the C3 glucuronic acid units of natural saponins MS I and II through an...
|
|
JP2022520384A |
The present invention relates to novel triterpene derivatives of formula (I) and pharmaceutically acceptable salts thereof. [Chemical 1] R1, R2, R3, R4 and ring structure [Chemical 2] Is as described herein. The present invention relates...
|
|
JP2022519714A |
The present invention provides a compound of formula (I) or a salt thereof: (formula (I)), wherein X, L, V, R1, R2, R3, And R4As defined herein. The patented compound inhibits the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) a...
|
|
JP7034078B2 |
Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.
|
|
JP7029542B2 |
Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.
|
|
JP2022516986A |
The present invention relates to steroid compounds, their use, and methods of their preparation. Such compounds can effectively treat psychiatric and neurological disorders, with good activity efficacy, pharmacokinetic (PK) performance, ...
|
|
JP6994201B2 |
Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious dis...
|
|
JP2022510475A |
The present invention relates to the following compound (I) mesylate (CH).3SO2) Regarding salt. [Selection diagram] None
|
